Ablon Skin Institute Research Center Report issue

Academic/Hospital

Organization Overview

First Clinical Trial
2013
NCT02297360
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Ablon Skin institute and Research Center | Ablon Skin Institute Research Center | Director Ablon Skin Institute Research Center

Active Ingredients

Drugs in Other Trials (1)

equisetum arvense sp (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 1